GSA Capital Partners LLP Increases Stake in ICU Medical, Inc. (NASDAQ:ICUI)

GSA Capital Partners LLP boosted its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 199.4% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,808 shares of the medical instruments supplier's stock after purchasing an additional 5,200 shares during the period. GSA Capital Partners LLP's holdings in ICU Medical were worth $1,423,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ICUI. Silvercrest Asset Management Group LLC grew its position in ICU Medical by 109.4% in the first quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier's stock worth $29,882,000 after acquiring an additional 145,485 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of ICU Medical by 2,966.3% during the 2nd quarter. Victory Capital Management Inc. now owns 141,848 shares of the medical instruments supplier's stock worth $16,844,000 after buying an additional 137,222 shares during the period. Millennium Management LLC raised its stake in ICU Medical by 327.8% during the 2nd quarter. Millennium Management LLC now owns 136,070 shares of the medical instruments supplier's stock valued at $16,158,000 after purchasing an additional 104,264 shares during the last quarter. Granite Investment Partners LLC acquired a new position in ICU Medical during the 2nd quarter valued at $10,650,000. Finally, F M Investments LLC acquired a new position in ICU Medical during the 2nd quarter valued at $10,175,000. 96.10% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ICUI has been the subject of several research analyst reports. StockNews.com cut shares of ICU Medical from a "buy" rating to a "hold" rating in a research note on Tuesday. Jefferies Financial Group initiated coverage on shares of ICU Medical in a research note on Monday, October 14th. They set a "hold" rating and a $183.00 target price for the company. KeyCorp upped their target price on shares of ICU Medical from $198.00 to $209.00 and gave the company an "overweight" rating in a research note on Wednesday. Needham & Company LLC reiterated a "hold" rating on shares of ICU Medical in a research note on Wednesday. Finally, Raymond James increased their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the company an "outperform" rating in a research note on Thursday, September 12th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $173.00.

Insider Buying and Selling at ICU Medical

In related news, VP Daniel Woolson sold 2,502 shares of the company's stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the transaction, the vice president now directly owns 13,107 shares in the company, valued at approximately $2,139,324.54. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, VP Daniel Woolson sold 2,502 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the transaction, the vice president now owns 13,107 shares of the company's stock, valued at approximately $2,139,324.54. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the company's stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $156.04, for a total value of $1,872,480.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company's stock, valued at $16,320,691.72. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,502 shares of company stock worth $8,445,976 over the last ninety days. Insiders own 6.70% of the company's stock.

ICU Medical Price Performance

NASDAQ:ICUI traded down $4.06 during mid-day trading on Thursday, reaching $170.75. 262,345 shares of the company were exchanged, compared to its average volume of 274,833. The company has a quick ratio of 1.08, a current ratio of 2.41 and a debt-to-equity ratio of 0.76. ICU Medical, Inc. has a 12 month low of $82.82 and a 12 month high of $196.26. The company has a fifty day moving average of $176.11 and a 200 day moving average of $141.98. The stock has a market cap of $4.17 billion, a PE ratio of -38.25 and a beta of 0.66.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The medical instruments supplier reported $1.23 EPS for the quarter, topping analysts' consensus estimates of $0.88 by $0.35. The business had revenue of $580.07 million for the quarter, compared to analyst estimates of $574.77 million. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.04%. On average, research analysts anticipate that ICU Medical, Inc. will post 3.81 EPS for the current fiscal year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.